Effect of Cnidii Rhizoma on nitric oxide production and invasion of human colorectal adenocarcinoma HT‑29 cells

Nam,Kyung‑Soo; Ha,Byung  Geun; Shon,Yun‑Hee

doi:10.3892/ol.2014.2660

Effect of Cnidii Rhizoma on nitric oxide production and invasion of human colorectal adenocarcinoma HT‑29 cells

Authors:
- Kyung‑Soo Nam
- Byung Geun Ha
- Yun‑Hee Shon
View Affiliations

Affiliations: Department of Pharmacology, College of Medicine, Dongguk University, Gyeongju, Gyeongsangbuk-do 780‑714, Republic of Korea, Bio‑Medical Research Institute, Kyungpook National University Hospital, Daegu 700‑721, Republic of Korea
Published online on: November 3, 2014 https://doi.org/10.3892/ol.2014.2660
Pages: 483-487

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal adenocarcinoma is the most common type of gastrointestinal cancer. Colon adenocarcinoma is a major health problem worldwide due to the high prevalence and mortality rates associated with the disease. The majority of colorectal carcinomas are adenocarcinomas, which originate from the epithelial cells of the colorectal mucosa. HT-29 cells, which originate from human colon adenocarcinoma, are used as an in vitro model to investigate the effect of malignant transformation on the expression of cellular constituents and functions of the intestinal epithelium. Nitric oxide (NO) is a signaling molecule, which is involved in inflammation and carcinogenesis. It has been reported that enhanced inducible NO synthase (iNOS) activity and the resulting NO concentrations in human colon carcinoma contribute to tumor progression and vascular invasion. The present study investigates the effect of pro‑inflammatory cytokine‑induced nitric oxide (NO) production and iNOS expression on the invasion of human colorectal adenocarcinoma HT‑29 cells, and the effect of extract from Cnidii Rhizoma on NO production and the invasiveness of HT‑29 cells. Treatment of HT‑29 cells with cytokines, 100 U/ml interferon γ, 10 ng/ml interleukin‑1 α and 25 ng/ml tumor necrosis factor α was found to increase NO production. Pretreatment of the cells with Cnidii Rhizoma (0.1‑5 mg/ml) resulted in an inhibition of cytokine‑induced NO production and iNOS expression. The invasiveness of HT‑29 cells through Matrigel was significantly increased by treatment with cytokines. Cnidii Rhizoma inhibited the invasiveness of cytokine‑treated HT‑29 cells through the Matrigel‑coated membrane in a concentration‑dependent manner. Matrix metalloproteinase (MMP) activity in HT‑29 cells increased following the treatment with cytokines, and pretreatment of the cells with Cnidii Rhizoma inhibited cytokine‑induced MMP‑2 activity. These results provide sufficient information for the further development of Cnidii Rhizoma as an antitumor metastatic agent for the treatment of colon cancer.

View Figures

View References

1	Choudhari SK, Chaudhary M, Bagde S, Gadbail AR and Joshi V: Nitric oxide and cancer: a review. World J Surg Oncol. 11:1182013. View Article : Google Scholar : PubMed/NCBI
2	Förstermann U and Sessa WC: Nitric oxide synthases: regulation and function. Eur Heart J. 33:829–837. 837a–837d. 2012. View Article : Google Scholar :
3	Tanese K, Grimm EA and Ekmekcioglu S: The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer. 131:891–901. 2012. View Article : Google Scholar :
4	Raina K, Agarwal C and Agarwal R: Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-kappaB signaling. Mol Carcinog. 52:195–206. 2013. View Article : Google Scholar :
5	Robert J: Biology of cancer metastasis. Bull Cancer. 100:333–342. 2013.(In French). PubMed/NCBI
6	Khokha R, Murthy A and Weiss A: Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 13:649–665. 2013. View Article : Google Scholar : PubMed/NCBI
7	Chaudhary AK, Pandya S, Ghosh K and Nadkarni A: Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview. Mutat Res. 753:7–23. 2013. View Article : Google Scholar : PubMed/NCBI
8	Langenskiöld M, Ivarsson ML, Holmdahl L, et al: Intestinal mucosal MMP-1 - a prognostic factor in colon cancer. Scand J Gastroenterol. 48:563–569. 2013. View Article : Google Scholar : PubMed/NCBI
9	Haranaka K, Satomi N, Sakurai A, et al: Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs. Cancer Immunol Immunother. 20:1–5. 1985. View Article : Google Scholar : PubMed/NCBI
10	Onishi Y, Yamaura T, Tauchi K, et al: Expression of the anti-metastatic effect induced by Juzen-taiho-to is based on the content of Shimotsu-to constituents. Biol Pharm Bull. 21:761–765. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kwak DH, Kim JK, Kim JY, et al: Anti-angiogenic activities of Cnidium officinale Makino and Tabanus bovinus. J Ethnopharmacol. 81:373–379. 2002. View Article : Google Scholar : PubMed/NCBI
12	Garvey EP, Oplinger JA, Furfine ES, et al: 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem. 272:4959–4963. 1997. View Article : Google Scholar : PubMed/NCBI
13	Menchén LA, Colón AL, Moro MA, et al: N-(3-(aminomethyl) benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Life Sci. 69:479–791. 2001. View Article : Google Scholar
14	Mertas A, Duliban H, Szliszka E, et al: N-[3-(aminomethyl)benzyl]acetamidine (1400W) as a potential immunomodulatory agent. Oxid Med Cell Longev. 2014:4912142014. View Article : Google Scholar
15	Bernard WS and Christopher PW: World Cancer Report 2014. International Agency for Research on Cancer, World Health Organization; Lyon, France: 2014
16	Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin. 59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
17	Fleming M, Ravula S, Tatishchev SF and Wang HL: Colorectal carcinoma: Pathologic aspects. J Gastrointest Oncol. 3:153–173. 2012.PubMed/NCBI
18	Kim M, Li YX, Dewapriya P, et al: Floridoside suppresses pro-inflammatory responses by blocking MAPK signaling in activated microglia. BMB Rep. 46:398–403. 2013. View Article : Google Scholar : PubMed/NCBI
19	Green LC, Wagner DA, Glogowski J, et al: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 126:131–138. 1982. View Article : Google Scholar : PubMed/NCBI
20	Hwang BM, Chae HS, Jeong YJ, et al: Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9. BMB Rep. 46:533–538. 2013. View Article : Google Scholar : PubMed/NCBI
21	Thomsen LL and Miles DW: Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev. 17:107–118. 1998. View Article : Google Scholar : PubMed/NCBI
22	Oktem G, Bilir A, Selvi N, et al: Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res. 16:195–203. 2006.PubMed/NCBI
23	Broholm H, Rubin I, Kruse A, et al: Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin Neuropathol. 22:273–281. 2003.PubMed/NCBI
24	Ramasamy K, Dwyer-Nield LD, Serkova NJ, et al: Silibinin prevents lung tumorigenesis in wild-type but not in iNOS−/− mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res. 17:753–761. 2011. View Article : Google Scholar :
25	Babu BR and Griffith OW: Design of isoform-selective inhibitors of nitric oxide synthase. Curr Opin Chem Biol. 2:491–500. 1998. View Article : Google Scholar : PubMed/NCBI
26	Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 1825:29–36. 2012.